AMGN vs VRTX

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus 9. 6% for Vertex Pharmaceuticals Incorporated (VRTX). Amgen Inc. (AMGN) offers the better valuation at 23. 3x trailing P/E (14. 8x forward), making it the more compelling value choice. Analysts rate Amgen Inc. (AMGN) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Amgen Inc.

(AMGN) is the cheapest at 23. 3x versus Vertex Pharmaceuticals Incorporated at 27. 9x. On forward P/E, Amgen Inc. is actually cheaper at 14. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Vertex Pharmaceuticals Incorporated wins at 2. 69x versus Amgen Inc. 's 5. 04x.

Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +100.

6%, compared to +48. 7% for Amgen Inc. (AMGN). Over 10 years, the gap is even starker: VRTX returned +399. 9% versus AMGN's +161. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amgen Inc.

(AMGN) is the lower-risk stock at 0. 60β versus Vertex Pharmaceuticals Incorporated's 0. 82β — meaning VRTX is approximately 36% more volatile than AMGN relative to the S&P 500. On balance sheet safety, Vertex Pharmaceuticals Incorporated (VRTX) carries a lower debt/equity ratio of 21% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus 9. 6% for Vertex Pharmaceuticals Incorporated (VRTX). On earnings-per-share growth, the picture is similar: Vertex Pharmaceuticals Incorporated grew EPS 836. 5% year-over-year, compared to 88. 2% for Amgen Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.

7% net margin versus 21. 0% for Amgen Inc. — meaning it keeps 32. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39. 4% versus 29. 1% for AMGN. At the gross margin level — before operating expenses — VRTX leads at 85. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Vertex Pharmaceuticals Incorporated (VRTX) is the more undervalued stock at a PEG of 2. 69x versus Amgen Inc. 's 5. 04x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Amgen Inc. (AMGN) trades at 14. 8x forward P/E versus 22. 3x for Vertex Pharmaceuticals Incorporated — 7. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VRTX: 29. 1% to $552. 27.

In this comparison, AMGN (2.

9% yield) pays a dividend. VRTX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), 2. 9% yield, +161. 5% 10Y return). Both have compounded well over 10 years (AMGN: +161. 5%, VRTX: +399. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

AMGN pays a dividend while VRTX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.